Table 1 Clinicopathological characteristics of the melanoma cohort treated with anti-PD-1 therapy
Characteristic | Anti-PD-1 patients, No. (%) | Objective response rate (CR/PR), No. (%) | Disease control rate (CR/PR/SD), No. (%) |
|---|---|---|---|
Overall | 116 (100) | 54 (47) | 80 (69) |
Age (y) | |||
  < 65 | 66 (57) | 33 (61) | 50 (62) |
  ≥ 65 | 50 (43) | 21 (39) | 30 (38) |
Sex | |||
 Male | 69 (59) | 34 (63) | 47 (58) |
 Female | 47 (41) | 20 (37) | 33 (42) |
Treatment | |||
 Pembrolizumab | 41 (35) | 20 (37) | 30 (38) |
 Nivolumab | 18 (16) | 7 (13) | 9 (11) |
 Ipilimumab plus nivolumab | 57 (49) | 27 (50) | 41 (51) |
Prior immune checkpoint blockade | |||
 Yes | 36 (31) | 14 (26) | 23 (29) |
 No | 80 (69) | 40 (74) | 57 (71) |
Mutation status | |||
 BRAF | 39 (33) | 19 (35) | 27 (34) |
 NRAS | 18 (16) | 8 (15) | 11 (14) |
 KIT | 2 (2) | 1 (2) | 2 (2) |
 None detected | 57 (49) | 26 (48) | 40 (50) |
Stage at diagnosis | |||
 I | 24 (21) | 14 (26) | 19 (24) |
 II | 23 (20) | 12 (22) | 16 (20) |
 III | 38 (32) | 16 (30) | 24 (30) |
 IV | 20 (17) | 6 (11) | 13 (16) |
 Not available | 11 (10) | 6 (11) | 8 (10) |